CJC-1295: No DAC vs With DAC — Which Version Should You Use?

Understanding the GHRH Foundation

Both versions of CJC-1295 are synthetic analogues of growth hormone releasing hormone (GHRH), the 44-amino-acid peptide produced by the hypothalamus that signals your pituitary to release stored growth hormone.

Natural GHRH has an extremely short half-life — approximately 7 minutes in circulation. It's degraded rapidly by dipeptidyl peptidase IV (DPP-IV) and other serum proteases. This brevity is by design. Your body releases GHRH in brief pulses, triggering corresponding GH pulses roughly 6-12 times per day, with the largest pulse occurring during deep sleep (Giustina & Veldhuis, 1998, Endocrine Reviews).

The original research goal was to create a GHRH analogue that resisted enzymatic degradation long enough to be therapeutically useful. This led to two fundamentally different engineering approaches.

---

Mod GRF 1-29 (CJC-1295 No DAC): The Pulsatile Approach

What It Is

Mod GRF 1-29 is a 29-amino-acid truncated analogue of GHRH with four amino acid substitutions at positions 2, 8, 15, and 27. These modifications protect the peptide from DPP-IV cleavage while preserving its biological activity at the GHRH receptor.

The "1-29" designation indicates it uses only the first 29 amino acids of the native 44-amino-acid GHRH sequence — the minimum fragment required for full receptor binding and activation (Ling et al., 1984, Biochemical and Biophysical Research Communications).

Pharmacokinetics

• Half-life: Approximately 30 minutes
• Peak GH release: 15-30 minutes post-injection
• GH elevation duration: 2-3 hours per administration
• Clearance: Essentially complete within 4 hours

Mechanism of Action

When injected, mod GRF 1-29 binds GHRH receptors on somatotroph cells in the anterior pituitary. This triggers a calcium-mediated signaling cascade that causes the release of stored GH granules — the same mechanism as your endogenous GHRH.

The critical point: because mod GRF 1-29 clears quickly, the pituitary receives a discrete signal, releases a pulse of GH, and then returns to baseline. This mimics the natural pattern of episodic GH secretion that drives IGF-1 production, tissue repair, fat metabolism, and sleep architecture.

Why Practitioners Prefer No DAC

The preference for mod GRF 1-29 over the DAC version among experienced clinicians and researchers comes down to physiological fidelity:

1. Preserved pulsatility: GH receptors downregulate under constant stimulation (Veldhuis et al., 2005, Journal of Clinical Endocrinology & Metabolism). Pulsatile delivery prevents tachyphylaxis.
2. Better GH receptor signaling: Pulsatile GH produces different downstream effects than tonic GH. The JAK2/STAT5 signaling pathway responds more robustly to amplitude rather than duration of GH exposure.
3. Maintained negative feedback: Between pulses, somatostatin tone recovers normally, preserving the hypothalamic-pituitary feedback loop.
4. Superior stacking: When combined with GHRPs (GHRP-6, GHRP-2, Ipamorelin, Hexarelin), the synergistic GH pulse amplitude can reach 5-10x baseline — an effect that's blunted with continuous GHRH stimulation.
5. Fewer side effects: Less water retention, less cortisol elevation, less prolactin disturbance.

---

CJC-1295 with DAC: The Sustained Approach

What It Is

CJC-1295 with DAC adds a Drug Affinity Complex — a reactive chemical moiety (maleimidopropionic acid linked to a lysine linker) that forms a covalent bond with serum albumin after injection. This albumin conjugation dramatically extends the peptide's circulating half-life by protecting it from proteolytic degradation and renal clearance.

The technology was developed by ConjuChem Biotechnologies (Montreal, Canada) and published extensively in clinical trial data (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism).

Pharmacokinetics

• Half-life: 8+ days (some estimates range to 10-14 days depending on individual albumin levels)
• Peak GH elevation: Gradual, reaching plateau over 24-48 hours
• GH elevation duration: Sustained for 6-10 days per injection
• Steady state: Achieved after 2-3 weekly injections

Mechanism of Action

After subcutaneous injection, the DAC moiety reacts with circulating albumin within minutes, forming a stable peptide-albumin conjugate. This massive complex (approximately 67 kDa with albumin vs 3.4 kDa for the free peptide) avoids glomerular filtration and resists proteolysis.

The result is a continuously circulating pool of active GHRH analogue that persistently stimulates pituitary somatotrophs. GH levels remain elevated above baseline 24/7 for the duration of the peptide's presence in circulation.

The Pulsatility Problem

Here's where the pharmacology gets problematic. Your pituitary gland was designed to respond to intermittent GHRH signals. Under continuous stimulation from DAC-CJC-1295:

• Somatostatin suppression weakens: The negative feedback loop becomes dysregulated
• GH pulse amplitude decreases: While baseline GH rises, the peak-to-trough ratio compresses (Ionescu & Bhatt, 2006, Hormone Research)
• Receptor desensitization risk: Sustained GHRH receptor occupancy can lead to reduced responsiveness over time
• IGF-1 elevation is sustained but non-physiological: The pattern of IGF-1 production differs from that generated by pulsatile GH

This doesn't mean CJC-1295 with DAC is ineffective — it demonstrably raises GH and IGF-1 levels in clinical trials. But it raises them in a pattern that diverges from normal physiology, with implications for long-term receptor health and downstream signaling efficiency.

---

Head-to-Head Comparison

Dosing Protocols

Mod GRF 1-29 (No DAC):

• Standard dose: 100 mcg per injection (some protocols use 50-200 mcg)
• Frequency: 2-3 times daily (upon waking, post-workout, before bed)
• Minimum effective protocol: 100 mcg before bed (single daily dose)
• Optimal protocol: 100 mcg 3x/day, combined with a GHRP at each administration
• Cycle length: 8-16 weeks, with periodic breaks recommended

CJC-1295 with DAC:

• Standard dose: 1,000-2,000 mcg (1-2 mg) per injection
• Frequency: Once or twice weekly
• Saturation: Typically 2 mg once weekly or 1 mg twice weekly
• Cycle length: 8-12 weeks with 4-week breaks

GH Output Comparison

Convenience Factor

This is where DAC wins unambiguously. Two injections per week versus six to twenty-one injections per week is a massive compliance difference. For individuals who:

• Travel frequently and can't maintain a 3x/day schedule
• Have injection fatigue
• Prefer simplicity over optimization
• Don't stack with GHRPs (eliminating the synergy argument)

The DAC version offers genuine practical advantage.

[Internal Link: /cjc-1295-dac/]

---

Side Effect Comparison

Mod GRF 1-29 (No DAC) — Side Effects

Common (>10% of users):

• Facial flushing immediately post-injection (15-30 seconds, resolves quickly)
• Mild hunger increase (especially when combined with GHRP-6)
• Injection site irritation

Uncommon (1-10%):

• Mild water retention (transient, resolves between doses)
• Lightheadedness immediately post-injection
• Tingling/numbness in extremities (brief)

Rare (<1%):

• Headache
• Hypoglycemia symptoms (if administered with GHRP during fasted state)

CJC-1295 with DAC — Side Effects

Common (>10% of users):

• Moderate to significant water retention (persistent while peptide is active)
• Facial flushing (prolonged compared to No DAC)
• Numbness and tingling in extremities (can persist hours to days)
• Joint stiffness (related to sustained GH/IGF-1 elevation)

Uncommon (1-10%):

• Headaches (sustained, correlating with persistent peptide levels)
• Carpal tunnel symptoms (CTS-like paresthesias from water retention)
• Fatigue paradox (excessive GH can impair sleep quality)
• Mild cortisol elevation

Rare (<1%):

• Pronounced edema requiring dose reduction
• Glucose intolerance with sustained use

The side effect differential is directly attributable to the sustained pharmacokinetic profile of the DAC version. When GH is elevated continuously, the body accumulates more interstitial fluid, experiences more prolonged IGF-1 mediated tissue effects, and doesn't get the recovery periods between pulses that allow normalization.

---

Stacking Considerations

Why No DAC is Superior for GHRP Stacking

The synergy between GHRH and GHRP (Growth Hormone Releasing Peptides) is well-documented. Administered simultaneously, they produce a GH pulse 2-3x greater than either alone (Bowers et al., 1990, Journal of Clinical Endocrinology & Metabolism). This synergy depends on timing — both peptides must hit their respective receptors during the same narrow window.

Mod GRF 1-29 is ideal for this because:

• You control exactly when the GHRH signal arrives
• You can time it precisely with your GHRP injection
• The combined pulse is discrete and powerful
• The pituitary recovers between combined administrations

With DAC, the GHRH component is always present. Adding a GHRP on top of continuous GHRH stimulation still produces a GH pulse, but the amplitude above the already-elevated baseline is reduced. The synergy is muted, not eliminated, but the ceiling is lower.

Optimal No DAC Stack Examples:

• Mod GRF 1-29 100 mcg + Ipamorelin 100-200 mcg (clean GH pulse, minimal side effects)
• Mod GRF 1-29 100 mcg + GHRP-2 100-200 mcg (stronger pulse, mild hunger/cortisol)
• Mod GRF 1-29 100 mcg + Hexarelin 100 mcg (maximum pulse amplitude, more side effects)

[Internal Link: /ipamorelin/] [Internal Link: /ghrp-2/]

When DAC Stacking Works

For individuals using DAC as a standalone GH elevation strategy — without GHRP combinations — the convenience and compliance benefits may outweigh the pulsatility loss. Some protocols add a single nightly GHRP dose on top of weekly DAC injections as a compromise approach.

---

Clinical Evidence

Mod GRF 1-29 Studies

Research on tesamorelin (a closely related GHRH analogue) and modified GRF analogues has demonstrated:

• Significant reduction in visceral adipose tissue (Falutz et al., 2007, New England Journal of Medicine)
• Improved body composition without changes in lean mass-specific metabolism
• Enhanced sleep quality and slow-wave sleep duration
• Preserved pulsatile GH secretion pattern

CJC-1295 with DAC Studies

The ConjuChem clinical trials (Phase I/II) demonstrated:

• Dose-dependent increases in GH and IGF-1 lasting 6-14 days after single injection
• Mean IGF-1 increases of 46-82% above baseline at therapeutic doses
• Sustained GH elevation above physiological pulsatile range
• Generally well-tolerated with injection site reactions as most common adverse event (Teichman et al., 2006)

---

Canadian Research Context

For Canadian researchers and clinicians, mod GRF 1-29 aligns with the Health Canada approach to growth hormone optimization — namely, that physiological replacement or enhancement should mimic endogenous patterns where possible. The concept of biomimetic hormone therapy favors pulsatile delivery systems across multiple endocrine axes.

Canadian peptide suppliers typically offer both versions, with mod GRF 1-29 generally available in 2 mg and 5 mg lyophilized vials for reconstitution. Storage and handling requirements are similar for both versions: refrigerated at 2-8°C after reconstitution, with bacteriostatic water as the standard reconstitution solvent.

[Internal Link: /bacteriostatic-water/]

---

Practical Decision Framework

Choose Mod GRF 1-29 (No DAC) If:

• You're stacking with any GHRP (Ipamorelin, GHRP-2, GHRP-6, Hexarelin)
• You want to preserve natural GH pulsatility
• You're sensitive to water retention
• You want rapid dose adjustment capability (can stop and clear within hours)
• You're running shorter protocols or cycling on/off
• You're focused on anti-aging and sleep quality optimization
• You prefer physiological approaches to supraphysiological ones

Choose CJC-1295 with DAC If:

• Injection frequency is a primary concern (travel, compliance, injection fatigue)
• You're not combining with GHRPs
• You want maximum IGF-1 elevation with minimum effort
• You're comfortable with sustained (non-pulsatile) GH elevation
• You've used No DAC protocols previously and tolerated GH elevation well
• Water retention is acceptable or manageable for your goals

---

Frequently Asked Questions

Can I switch between No DAC and DAC versions mid-protocol?

Yes, but allow the DAC version to clear (approximately 2-3 half-lives, so 16-24 days) before expecting normal pulsatile responses from the No DAC version. The persistent GHRH signal from residual DAC-CJC-1295 will blunt the discrete pulse effect of mod GRF 1-29 if both are active simultaneously.

Is mod GRF 1-29 the same as Sermorelin?

No. Sermorelin is the first 29 amino acids of native GHRH without the protective amino acid substitutions. It retains the DPP-IV cleavage site at position 2, giving it a half-life of approximately 10-12 minutes — better than native GHRH but significantly shorter than mod GRF 1-29's 30-minute half-life. Mod GRF 1-29 is the superior research compound for consistent GH stimulation per injection.

Does CJC-1295 with DAC suppress natural GH production?

Not through direct negative feedback on GHRH production itself, but through secondary mechanisms. Sustained GH elevation increases somatostatin tone and elevates IGF-1, both of which suppress endogenous GH pulse amplitude. Upon discontinuation, the hypothalamic-pituitary axis recovers — typically within 2-4 weeks — but there may be a period of blunted GH output during this recovery phase.

What's the minimum effective dose of mod GRF 1-29?

Research suggests the saturation dose for the GHRH receptor on pituitary somatotrophs is approximately 1 mcg/kg body weight — roughly 100 mcg for a 100 kg individual. Going higher doesn't proportionally increase GH output because receptor occupancy plateaus. The standard 100 mcg dose is appropriate for most adults regardless of body weight, as receptor density (not body mass) is the limiting factor.

Can women use CJC-1295 (either version)?

Yes. GH physiology is largely sex-independent at the level of GHRH receptor response. Women naturally have higher GH pulse frequency but lower amplitude compared to men, and both versions of CJC-1295 are effective across sexes. Dosing is typically identical. Women may experience slightly more pronounced water retention with the DAC version due to interactions between estrogen and GH-mediated fluid dynamics.

---

Conclusion

The CJC-1295 No DAC versus DAC decision ultimately comes down to whether you prioritize physiological fidelity or injection convenience. For the majority of protocols — particularly those involving GHRP combinations, anti-aging applications, and body composition optimization — mod GRF 1-29 (No DAC) is the superior choice. It preserves the pulsatile GH secretion pattern your endocrine system was built around, minimizes side effects, enables powerful GHRP synergy, and allows precise dose timing.

The DAC version has its place: when compliance is paramount, when GHRP stacking isn't planned, or when sustained IGF-1 elevation is the specific goal. But understand that you're trading physiological elegance for convenience — and for most researchers, that trade-off favors the No DAC version.

[Internal Link: /cjc-1295-no-dac/] [Internal Link: /cjc-1295-dac/]

---

This article is for educational and informational purposes only. Peptides discussed are intended for research use. Consult a qualified healthcare provider before beginning any peptide protocol.